What versions of talatumumab are there? How much do they cost? _ Kanghule

Talatuzumab is a new type of immunotherapy drug that is currently produced globally only by the American company Amgen and has been approved for marketing in the United States. It is used to treat adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after platinum-based chemotherapy. Talatumumab has shown significant therapeutic potential due to its unique mechanism, but information on its market availability and price are equally important to patients and medical institutions.

What are the versions of talatumumab?

Currently there is only one drug form, namely freeze-dried powder injection for intravenous injection, but there are two packaging versions with different specifications to meet different treatment needs.

1 mg version

The 1 mg version of talatumumab is indicated for use on the first day of the initial treatment cycle as part of a dose escalation regimen. This version starts at a lower dose and is designed to reduce the risk of serious adverse reactions such as cytokine release syndrome (CRS).

10 mg strength version

The 10 mg strength version is the standard therapeutic dose of talatumumab and is used for subsequent days of the initial treatment cycle and subsequent treatment cycles. This version ensures that patients continue to receive effective therapeutic doses to maintain and enhance therapeutic effects.

How much do different versions of talatumumab cost?

The price of talatumumab varies depending on factors such as specifications, regions, and market supply. The following price information is based on reference data in 2025 and is for reference only.

Price of the 1 mg strength version

The price of the 1 mg strength version of Talatumumab is US$6,102 per box. Because this version is only used on the first day of the initial treatment cycle, its financial burden is relatively small relative to the entire treatment cycle.

Price of the 10mg version

The price of the 10mg version as the standard therapeutic dose is US$28,129 per box. Considering that patients need to continue receiving treatment for multiple cycles, the price of this version forms a major part of the cost of treatment. However, the specific treatment cost needs to be calculated comprehensively based on factors such as the patient's treatment cycle, dose adjustment, and treatment of complications.

The efficacy of talatumumab

Talatumumab is an innovative T cell adapter therapy that activates T cells to kill tumor cells by simultaneously targeting the DLL3 protein on the surface of tumor cells and the CD3 protein on the surface of T cells. Its efficacy has been fully verified in clinical studies.

Supported by clinical research data

In the pivotal clinical study Study DeLLphi-301, talatumumab showed encouraging efficacy. The study results show that the drug has a high overall response rate (ORR). In addition, the median duration of response (DOR) was also longer.

Efficacy in patients with different platinum sensitivity status

Talatuzumab has shown certain efficacy in patients with different platinum sensitivity status. In Study DeLLphi-301, the ORR was higher for patients with platinum resistance (time to progression less than 90 days), and talatumumab has certain therapeutic potential in different patient groups.

Talatumumab is currently available in two specifications: 1mg and 10mg, and the price varies depending on the specifications. Its efficacy has been fully verified in clinical studies, and it has shown certain therapeutic potential for patients with different platinum-sensitive states.